Seattle Genetics Inc (SGEN)

45.32
0.04 0.09
NASDAQ : Health Care
Prev Close 45.36
Open 45.23
Day Low/High 45.17 / 46.07
52 Wk Low/High 26.02 / 49.66
Volume 531.18K
Avg Volume 747.50K
Exchange NASDAQ
Shares Outstanding 140.52M
Market Cap 6.37B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Analysts' Actions -- Alaska Air, Southwest, Coach, Twitter and More

Analysts' Actions -- Alaska Air, Southwest, Coach, Twitter and More

Here are Wednesday's top research calls, including upgrades for Coach and Alaska Air, and downgrades for Southwest Airlines and Twitter.

Seattle Genetics Reports Second Quarter 2016 Financial Results

Seattle Genetics Reports Second Quarter 2016 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the second quarter ended June 30, 2016.

Seattle Genetics And Takeda Announce Publication Of Final Data From ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood

Seattle Genetics And Takeda Announce Publication Of Final Data From ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood

Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced the final data of the ADCETRIS (brentuximab vedotin) monotherapy pivotal Phase 2 clinical trial in relapsed...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter 2016 Financial Results On July 26, 2016

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter 2016 Financial Results On July 26, 2016

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets.

Seattle Genetics Announces European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) As Consolidation Treatment In Post-Transplant Hodgkin Lymphoma

Seattle Genetics Announces European Commission Approval Of ADCETRIS® (Brentuximab Vedotin) As Consolidation Treatment In Post-Transplant Hodgkin Lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its collaborator Takeda Pharmaceutical Company, Limited, received marketing authorization by the European Commission for ADCETRIS (brentuximab vedotin) for the...

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

5 Best-Positioned Biotech Stocks on Brexit Volatility

5 Best-Positioned Biotech Stocks on Brexit Volatility

Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of The European Hematology Association

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of The European Hematology Association

-Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 76 Percent Objective Response Rate, Including a 41 Percent Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 33A Combination Therapy-

Insider Trading Alert - ELGX, SGEN And JYNT Traded By Insiders

Insider Trading Alert - ELGX, SGEN And JYNT Traded By Insiders

Stocks with insider trader activity include ELGX, SGEN and JYNT

Astellas And Seattle Genetics Present ASG-15ME And ASG-22ME Phase I Clinical Data In Metastatic Urothelial Cancer At ASCO Annual Meeting

Astellas And Seattle Genetics Present ASG-15ME And ASG-22ME Phase I Clinical Data In Metastatic Urothelial Cancer At ASCO Annual Meeting

-Clinical Data Indicating Antitumor Activity Presented from Two Antibody-Drug Conjugate Programs-

Stock To Watch: Seattle Genetics (SGEN) In Perilous Reversal

Stock To Watch: Seattle Genetics (SGEN) In Perilous Reversal

Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "perilous reversal" (up big yesterday but down big today) candidate

Seattle Genetics (SGEN) Is Strong On High Volume Today

Seattle Genetics (SGEN) Is Strong On High Volume Today

Trade-Ideas LLC identified Seattle Genetics (SGEN) as a strong on high relative volume candidate

Seattle Genetics Initiates Pivotal Phase 3 Trial Of Vadastuximab Talirine (SGN-CD33A) For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Seattle Genetics Initiates Pivotal Phase 3 Trial Of Vadastuximab Talirine (SGN-CD33A) For Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Seattle Genetics, Inc. (NASDAQ: SGEN) today announced initiation of a pivotal phase 3 clinical trial, called CASCADE, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) or...

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences.

Seattle Genetics Reports First Quarter 2016 Financial Results

Seattle Genetics Reports First Quarter 2016 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the first quarter ended March 31, 2016.

Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted multiple data presentations that support several of the company's antibody-drug conjugate (ADC) and immuno-oncology programs featured at the upcoming 107 th...

Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted novel antibody-drug conjugate (ADC) technology advances presented at the 107 th Annual Meeting of the American Association for Cancer Research (AACR) being held...

Weak On High Volume: Seattle Genetics (SGEN)

Weak On High Volume: Seattle Genetics (SGEN)

Trade-Ideas LLC identified Seattle Genetics (SGEN) as a weak on high relative volume candidate

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter 2016 Financial Results On April 28, 2016

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter 2016 Financial Results On April 28, 2016

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2016 financial results on Thursday, April 28 after the close of financial markets.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics To Present At Upcoming Investor Conferences

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences.

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD19B For Patients With B-cell Non-Hodgkin Lymphoma

Seattle Genetics Initiates Phase 1 Trial Of SGN-CD19B For Patients With B-cell Non-Hodgkin Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1 clinical trial of SGN-CD19B for relapsed or refractory patients with two subtypes of B-cell non-Hodgkin lymphoma (NHL): diffuse large B-cell...

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Seattle Genetics Initiates Phase 1/2 Trial Of Vadastuximab Talirine (SGN-CD33A) Combination Therapy For Patients With Untreated Myelodysplastic Syndrome (MDS)

Seattle Genetics Initiates Phase 1/2 Trial Of Vadastuximab Talirine (SGN-CD33A) Combination Therapy For Patients With Untreated Myelodysplastic Syndrome (MDS)

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1/2 clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) in patients with previously untreated...

Seattle Genetics (SGEN) Is Today's Dead Cat Bounce Stock

Seattle Genetics (SGEN) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Analysts' Actions -- Coca-Cola, Hess, Randgold, Yelp and More

Analysts' Actions -- Coca-Cola, Hess, Randgold, Yelp and More

Here are Wednesday's top research calls, including upgrades for Coca-Cola, Hess and Randgold, and a downgrade for Yelp.

Post-Market Laggard: Seattle Genetics (SGEN)

Post-Market Laggard: Seattle Genetics (SGEN)

Trade-Ideas LLC identified Seattle Genetics (SGEN) as a post-market laggard candidate